Meet the new Tandem Mobi system at the 84th Scientific Sessions in Orlando, FL. Visit Tandem Diabetes Care Booth #1621

This information is being distributed by the American Diabetes Association as a sponsor benefit. Reference to commercial products, processes, or services by trade name, trademark, manufacturer, or otherwise, does not necessarily constitute or imply its endorsement, recommendation, or favoring by the American Diabetes Association. The views and opinions of sponsors expressed herein do not necessarily state or reflect those of the American Diabetes Association, and shall not be used for advertising or product endorsement purposes.

Don’t miss out on meeting Tandem Mobi, the world’s smallest, durable automated insulin delivery system¹ from Tandem Diabetes Care.

Learn about data presented at their product theater and explore the benefits of the impressively small AID system that offers wearability like never before.

Visit booth 1621 for more information about Tandem Mobi, the tiny pump that’s big on control.

Reference

As of June, 2024. Data on file, Tandem Diabetes Care.

Important Safety Information: RX ONLY. Indications for Use: Tandem Mobi system: The Tandem Mobi insulin pump with interoperable technology (the pump) is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The pump is intended for single patient, home use and requires a prescription. The pump is indicated for use in individuals 6 years of age and greater. Control-IQ technology: Control-IQ technology is intended for use with compatible integrated continuous glucose monitors (iCGM, sold separately) and alternate controller enabled (ACE) pumps to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold. Control-IQ technology is intended for the management of Type 1 diabetes mellitus in persons 6 years of age and greater. Control-IQ technology is intended for single patient use. Control-IQ technology is indicated for use with NovoLog or Humalog U-100 insulin.

WARNING: Control-IQ technology should not be used by anyone under the age of 6 years old. It should also not be used in patients who require less than 10 units of insulin per day or who weight less than 55 pounds.

Control-IQ technology is not indicated for use in pregnant women, people on dialysis, or critically ill patients. Do not use Control-IQ technology if using hydroxyurea. Users of a Tandem insulin pump and Control-IQ technology must use the insulin pump, CGM, and all other system components in accordance with their respective instructions for use; test blood glucose levels as recommended by their healthcare provider; demonstrate adequate carb-counting skills; maintain sufficient diabetes self-care skills; see healthcare provider(s) regularly; and have adequate vision and/or hearing to recognize all functions of the pump, including alerts, alarms, and reminders. The Tandem pump and the CGM transmitter and sensor must be removed before MRI, CT, or diathermy treatment. Visit tandemdiabetes.com/safetyinfo for additional important safety information.

©2024 Tandem Diabetes Care, Inc. All rights reserved. Tandem Diabetes Care, Tandem logos, Control-IQ technology, and Tandem Mobi are registered trademarks of Tandem Diabetes Care, Inc. in the United States and/or other countries. CM-003339_A

Learn more